Ab Studio designed antibodies are at clinical stages! GB261, an Fc-Function Enabled and CD3 Affinity De-Tuned CD20/CD3 Bispecific Antibody designed by Ab Studio shows promising new results published in ASH's annual meeting.   Click here for more information.


Using our proven technology of computer-design and on-bench validation, SEND US YOUR PROTEIN SEQUENCE and we will provide a drug candidate OFFERING IMPROVED BALANCE OF SAFETY, EFFICACY, AND MANUFACTURABILITY.  


Multispecific Antibody Discovery Platform - Bring us your targets, we’ll handle the specifics

view pdf

Internalizing Antibody Platform - Our internalizing antibodies strike cancer from within

view pdf

Imbalanced Bispecific Antibody Platform - Achieve safety/efficacy harmony with affinity tuning

view pdf
  • Ab Studio’s robust computer-aided platforms, on-bench validation, and expertise in antibody design and optimization has led to promising clinical programs from both out-licensed assets and CRO projects.
  • We welcome the opportunity for collaboration! Please contact us to start a discussion.

3541 Investment Blvd. Suite 3,
Hayward, CA 94545 USA